Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$3.23 +4.5%	$2.71	$1.69 ▼ $6.90	$7.96M	2.04	95,378 shs	1.34 million shs
ESLA Estrella Immunopharma	$0.85 -1.8%	$0.91	$0.63 ▼ $1.78	$31.28M	0.34	16,666 shs	3,515 shs
ITRM Iterum Therapeutics	$0.82 +5.6%	$0.91	$0.66 ▼ $3.02	$34.52M	2.85	1.05 million shs	1.39 million shs
KZR Kezar Life Sciences	$3.92 +0.5%	$4.37	$3.62 ▼ $9.18	$28.49M	0.65	59,617 shs	47,522 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	+5.82%	+4.39%	+6.19%	+51.47%	-9.38%
ESLA Estrella Immunopharma	-1.93%	+2.37%	-1.69%	-12.63%	-38.21%
ITRM Iterum Therapeutics	+8.23%	+11.16%	-31.59%	-17.73%	-31.59%
KZR Kezar Life Sciences	-0.76%	-4.18%	-13.53%	-5.57%	-34.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELZ Creative Medical Technology	0.5694 of 5 stars	0.0	2.0	0.0	3.9	0.0	0.6
ESLA Estrella Immunopharma	3.1378 of 5 stars	3.5	5.0	0.0	3.3	1.7	0.0
ITRM Iterum Therapeutics	2.2302 of 5 stars	3.5	3.0	0.0	2.2	1.7	0.0
KZR Kezar Life Sciences	3.8196 of 5 stars	3.2	1.0	4.6	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELZ Creative Medical Technology	0.00	N/A	N/A	N/A
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,783.02% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	1,002.13% Upside
KZR Kezar Life Sciences	2.33	Hold	$39.50	907.65% Upside

Current Analyst Ratings Breakdown

Latest CELZ, ITRM, ESLA, and KZR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELZ Creative Medical Technology	$10K	833.34	N/A	N/A	$2.65 per share	1.22
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	$0.12 per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.09) per share	N/A
KZR Kezar Life Sciences	$7M	4.09	N/A	N/A	$16.02 per share	0.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELZ Creative Medical Technology	-$5.49M	-$3.18	N/A	N/A	N/A	N/A	-82.99%	-79.49%	N/A
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-354.91%	9/26/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.85	N/A	∞	N/A	N/A	N/A	-65.01%	N/A
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	N/A

Latest CELZ, ITRM, ESLA, and KZR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KZR Kezar Life Sciences	-$2.25	-$1.87	+$0.38	-$1.87	N/A	N/A
8/8/2025	Q2 2025	CELZ Creative Medical Technology	-$0.63	-$0.48	+$0.15	-$0.48	N/A	N/A
8/5/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELZ Creative Medical Technology	N/A	23.86	27.42
ESLA Estrella Immunopharma	N/A	0.22	0.22
ITRM Iterum Therapeutics	N/A	2.69	2.52
KZR Kezar Life Sciences	0.04	7.09	7.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELZ Creative Medical Technology	1.42%
ESLA Estrella Immunopharma	0.35%
ITRM Iterum Therapeutics	9.21%
KZR Kezar Life Sciences	67.90%

Insider Ownership

Company	Insider Ownership
CELZ Creative Medical Technology	2.80%
ESLA Estrella Immunopharma	55.10%
ITRM Iterum Therapeutics	2.40%
KZR Kezar Life Sciences	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELZ Creative Medical Technology	5	2.58 million	2.51 million	Not Optionable
ESLA Estrella Immunopharma	N/A	36.17 million	16.24 million	Not Optionable
ITRM Iterum Therapeutics	10	44.66 million	43.59 million	Not Optionable
KZR Kezar Life Sciences	60	7.31 million	6.55 million	Not Optionable

CELZ, ITRM, ESLA, and KZR Headlines

Recent News About These Companies

Kezar Narrows Loss 37 Percent in Q2

2 hours ago | aol.comA

Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)

2 hours ago | msn.com

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

August 13 at 4:19 PM | businesswire.com

Kezar Life Sciences (KZR) to Release Earnings on Tuesday

August 11 at 2:46 AM | americanbankingnews.com

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

August 9, 2025 | americanbankingnews.com

Kezar sees hepatitis hold lifted, hints at resurrecting lupus program

July 16, 2025 | fiercebiotech.comF

FDA lifts partial hold on Kezar’s zetomipzomib trial

July 16, 2025 | thepharmaletter.comT

Kezar Life Sciences Says FDA Lifts Clinical Hold

July 16, 2025 | marketwatch.com

Kezar Life Sciences stock gains after FDA lifts partial clinical hold

July 16, 2025 | uk.investing.com

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

July 15, 2025 | businesswire.com

Kezar Life Sciences Inc. Research & Ratings | KZR | Barron's

July 13, 2025 | barrons.com

KZR | Kezar Life Sciences Inc. Stock Overview (U.S.: Nasdaq) - Barron's

June 30, 2025 | barrons.com

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

May 27, 2025 | zacks.com

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | businesswire.com

Kezar toplines small Phase 2a dataset in autoimmune liver disease

March 27, 2025 | endpts.comE

Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo

March 27, 2025 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)

March 26, 2025 | markets.businessinsider.com

Kezar Life Sciences reports topline results from PORTOLA trial

March 26, 2025 | markets.businessinsider.com

Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

March 25, 2025 | seekingalpha.com

Kezar drops after Q4 results and mid-stage data for lead asset

March 25, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CELZ, ITRM, ESLA, and KZR Company Descriptions

Creative Medical Technology NASDAQ:CELZ

$3.23 +0.14 (+4.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.14 -0.09 (-2.79%)

As of 07:52 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Estrella Immunopharma NASDAQ:ESLA

$0.85 -0.02 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.84 -0.01 (-0.91%)

As of 07:46 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Iterum Therapeutics NASDAQ:ITRM

$0.82 +0.04 (+5.64%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.02 (+2.01%)

As of 07:59 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Kezar Life Sciences NASDAQ:KZR

$3.92 +0.02 (+0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 +0.04 (+1.05%)

As of 04:32 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time